Arca
Skip to content
Tools
Tools

ENG: Endoglin

Vascular endothelium glycoprotein that plays an important role in the regulation of angiogenesis.

  • Drugs that act on it: 1
  • Approved: 0
  • In phases 1 to 3: 1
  • Sponsors: 1

Who is on it, and how far along

Every drug ChEMBL records acting on ENG, by the furthest stage it has reached for any use, coloured by modality.

How to read this

Each mark is one drug. Columns run from approved to phase 1; hover or tap a mark for its sponsor, modality and open trials, and click it to open the drug.

  • Antibody 1

Approved0

    Phase 31

    • Carotuximab

    Phase 20

      Phase 10

        The landscape

        Every drug acting on it, furthest along first. The sponsor is the US application holder where there is one, else the industry lead sponsor of most of its registered trials.
        DrugFurthest stageSponsorModalityActionOpen trials
        CarotuximabPhase 3Tracon PharmaceuticalsAntibodyInhibitorEndoglin inhibitor2

        Open trials

        The most recently posted recruiting or ongoing trials naming each drug (up to 8 a drug), 2 in all, from ClinicalTrials.gov.
        Study of AR Suppression With Carotuximab in Metastatic, Castration-Resistant Prostate CancCarotuximabPhase 2RecruitingEdwin Posadas, MDSep 9, 2022
        Study of Osimertinib With Carotuximab in Advanced, EGFR-mutated Non-Small Cell Lung CancerCarotuximabPhase 1RecruitingKaren Reckamp, MD, MSJun 2, 2022

        Diseases most associated with it

        Open Targets association score, 0 to 1; all associations
        • Telangiectasia, hereditary hemorrhagic, type 10.85
        • Vascular disorder0.60
        • Arteriovenous hemangioma/malformation0.59
        • Capillary disorder0.58
        • Capillary malformation0.57
        • Congenital anomaly of the great arteries0.57
        • Abnormality of the cardiovascular system0.56
        • Abnormality of the vasculature0.55
        • Congenital anomaly of cardiovascular system0.55
        • Abnormal cardiovascular system morphology0.55
        • Congenital vascular malformation0.53

        Drugs, mechanisms, furthest stage (max phase) and modality (molecule type) are from ChEMBL CHEMBL3712885, ChEMBL 37, fetched 2026-11-18 (CC BY-SA 3.0). Sponsors are the US application holder (Drugs@FDA) for approved drugs with a US page, else the industry lead sponsor of the most of the drug's ClinicalTrials.gov trials. Open trials are recruiting or ongoing studies naming the drug as an intervention on ClinicalTrials.gov, checked daily; this page as of 2026-11-21. Gene name, function (UniProt P17813, CC BY 4.0) and disease associations are from Open Targets (CC0). ChEMBL and Open Targets

        Esc

        Type a name: a tool, a company, a drug or brand, a condition, a gene or a state. Identifiers like K231234, NCT05012345 or NDA 215866 open their record.

        Logos are each company's own site icon, matched by name through Wikidata, or logos provided by Logo.dev.Company names and logos identify the companies in public FDA and registry records and do not imply endorsement.